A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide

Part of paid clinical trials in Baton Rouge, Louisiana.

Sponsor
Eli Lilly and Company
Study ID
NCT04081337
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • Tirzepatide — DRUG
    Administered SC
  • Placebo — DRUG
    Administered SC

Study Details

This is a study of tirzepatide in participants with obesity. The main purpose is to learn more about how tirzepatide affects the number of calories participants burn and the amount of food they eat. The study lasted for 28 weeks and will include about 21 visits to the study center.

Key Dates

Start date
Jul 9, 2020
Status verified
May 2023
Primary completion
May 26, 2022
Completion
May 26, 2022

Study Design

Enrollment
55 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Placebo Comparator: Placebo
    Participants received placebo once weekly (QW) by Subcutaneous (SC) injection.
  • Experimental: 15 Milligram (mg) Tirzepatide
    Participants received 15 mg of tirzepatide QW by SC injection.

Primary Outcome Measure

Change From Baseline to Week 18 in Sleep Metabolic Rate (SMR) [ Time Frame: Baseline, Week 18 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Pennington Biomedical Research CenterBaton RougeLouisiana70808-

Find similar trials in Baton Rouge, LA

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Pennington Biomedical Research Center· Baton Rouge, LA

Related Studies